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Abstract
The relationship between Alzheimer's disease (AD) and progressive degeneration of the forebrain
cholinergic system is very well established, whereas mechanisms linking this disease with
cholesterol, apolipoprotein E (apoE) phenotype, and amyloid precursor protein (APP) metabolism
have not been fully elucidated even though there is a plethora of publications separately on each of
these issues. The intention of this hypothesis is to unify knowledge coming from all of these areas.
It is based on an assumption that the process of APP hypermetabolism is a neuroprotective
response for age-related cholinergic deterioration. In some individuals this initially positive process
becomes highly overregulated by genetic or/and epigenetic risk factors and after many years of
accumulations lead eventually to AD. I hypothesise that neuroprotective role of APP-
hypermetabolism might be related to enrichment of neuronal membranes (lipid rafts in particular)
in cholesterol in order to compensate for decrease in presynaptic cholinergic transmission and/or
AD-related decrease in cholesterol levels. The above is consistent with findings indicating that
activity of both muscarinic and nicotinic cholinergic receptors is correlated in a positive manner
with cholesterol plasmalemmal content. Briefly – APP metabolism together with transport of
cholesterol in apoE containing lipoproteins seem to play a key role in mobilising cholesterol into
neuronal membranes.
Background
The role of cholesterol in Alzheimer's disease (AD) is
attracting increasing attention of researchers [1] and there
are conflicting messages coming form a great deal of
reports. Despite the fact that a wide-spread opinion about
high levels of this lipid in the organism still remains neg-
ative, there is a growing body of evidence suggesting its
beneficial role in the brain. It is for example corroborated
by the study showing that high cholesterol blood levels
correlate with a lower mortality index and a better out-
come following a first stroke [2]. There was also a positive
relationship between a hypercholesterolemic diet and
improved preservation of cognitive functions in rats
which previously underwent anoxic period [3]. The signif-
icance of the results obtained with the use of a dietetic par-
adigm has recently been confirmed by findings reporting
a net flux of peripheral cholesterol through Blood-Brain
Barrier in the form of 27-hydroxycholesterol [4]. It has
also been found that patients suffering from AD have
lower levels of cholesterol in cerebrospinal fluid[5] in the
lipid fraction of brain membranes resulting in altered
membrane physical properties [6] and recently in choles-
terol-enriched lipid microdomains in plasmalemma –
lipid rafts [7]. Moreover a relationship between AD and
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down-regulation of seladin-1; a protein involved in cho-
lesterol synthesis was found, reviewed in [7] which may
be due to a genetic disorder.
It appears that cholesterol has universal neuroprotective
properties. However for the purpose of this article this
activity will be described only in connection to AD.
The hypothesis combines within one unifying concept
well established facts from the three following main
streams of AD research:
- the prevalence of forebrain cholinergic system deficits in
the disease development, – metabolism of amyloid pre-
cursor protein (APP) and
- the role of apolipoprotein E4 (apoE4) isoform as a risk
factor in association with cholesterol metabolism in the
brain.
These key issues will be briefly introduced before present-
ing the hypothesis.
The main type of neurons primarily affected by AD are
these belonging to and innervated by the cholinergic fore-
brain projection. It is a neuromodulatory system related
to high cognitive functions. Deficits in these commands
are the first clinical manifestations of AD [8].
Forebrain cholinergic neurons and areas extensively
innervated by them (hippocampus and neocortex) con-
tain the largest amounts of senile plaques. According to
amyloid cascade hypothesis, widely accepted by scientists,
senile plaques are primary factors causing neuronal death
in AD, whereas neurofibrillary tangles are secondary [9].
The major constituent of senile plaques are peptides
called β -amyloids, products of enzymatic cleavage of APP.
Formation of senile plaques is a result of many years of
accumulation of β -amyloids and other peptides forming
extracellular insoluble aggregates. However it appears that
in shorter periods APP and its metabolites demonstrate
neuroprotective activity. The increased deposition of APP
is a relatively quick reaction to factors deteriorating brain
functioning, see for example:[10]. Direct neuroprotective
effects were shown in the rat hippocampus [11]. They also
were reported to protect cognitive functions following
application of anticholinergic agent [12]. Recently Koudi-
nov and Berezov have reviewed evidence showing a posi-
tive role of β -amyloids in the brain [13].
Cholinergic neurons display particular vulnerability to
any negative factors affecting brain function, see for exam-
ple: [14-16]. Ageing is a major process causing chronic
deterioration of brain functioning, the cholinergic system
being particularly susceptible and inducing long lasting
overproduction of β -amyloids. If this process is aggra-
vated by genetic and/or epigenetic factors it may eventu-
ally lead to development of AD.
The importance of cholesterol in the brain functioning is
suggestively reflected by the fact that the human brain
making up only 2% of total body weight contains as much
as 25% of the total pool of this lipid [17]. To a big extent
it is concentrated in myelin sheath. However there are also
considerable amounts also in neuronal plasmalemma
and in lipid rafts in particular. Lipid rafts seem to play a
key role in transmembrane signalling processes, including
synaptic transmission [18]. Importantly, APP is suggested
to occur in lipid rafts [19,20].
The hypothesis aims at explaining this positive role of
cholesterol in the brain in association with geriatric
cholinergic deficits and APP metabolism.
Presentation of the hypothesis
As suggested above age-related dysfunction in the fore-
brain cholinergic system results in APP hypermetabolism.
However the mechanisms by which APP metabolites fulfil
their neuroprotective functions despite some attempts,
have not been fully elucidated. I hypothesise that these
properties are due to the involvement of APP metabolites
in the process of internalization of lipoproteins labelled
with apoE, enriched with cholesterol. What could be the
aim of this process ? There are data indicating a positive
dependence of cholinergic receptors (both muscarinic
and nicotinic) on cholesterol content in plasma mem-
branes [21] and the mechanism of molecular interactions
between cholesterol and nicotinic receptors have been
proposed [22]. In contrast, receptors for monoaminergic
agonists, seem to be negatively modulated by high mem-
brane cholesterol [21,23]. In this respect increased uptake
of cholesterol might be at least in part a process aiming at
compensating cholinergic deficits and/or cholesterol defi-
cits in AD caused for instance by genetic factors. Within
the framework of this concept it is possible to explain the
causal relationship between AD and a phenotype of apoE.
The importance of apoE containing lipoproteins in neu-
roregenerative processes in connection to the role of cho-
lesterol seems to be well established [20,24], although the
role of APP and relationship of apoE-dependent transport
with cholinergic transmission has not been fully clarified,
despite some interesting proposals [24], which may be
regarded as complementary to this hypothesis. There are
three allele: ε 2, ε 3 and ε 4 coding different isoforms of the
protein. Expression of apoE4 isoform increases the risk of
both sporadic and familial late onset of AD. Consequently
one can assume that a higher demand of neurons for cho-
lesterol results in higher production of β -amyloids which
are engaged in internalization of apoE containing lipo-
proteins. Possibly interaction between the apoE4 isoformLipids in Health and Disease 2005, 4:13 http://www.lipidworld.com/content/4/1/13
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and  β -amyloids in contrast to other isoforms is more
prone to accumulation of insoluble aggregates and in
addition might be less effective in cholesterol uptake as
suggested in[20]. The relationship between levels of
expression of APP metabolites, amount of apoE and cho-
lesterol levels has been shown in several instances. An
interesting example of such a relationship is provided by
Howland et al [25] who carried out experiments exploring
a mouse model of AD. In these mice exposure to a high
cholesterol diet resulted in reduction of APP metabolites
and concomitant increase of apoE. Similarly, it was
reported that cells in culture exposed to high cholesterol
reduced APP metabolism [26]. Reduction in APP metabo-
lite production in conditions of high cholesterol in these
publications may be explained by the negative feedback
principle.
Testing the hypothesis
The best way to test the hypothesis might be by experi-
ments combining all of its main constituents. For instance
by inducing APP hypermetabolism, and then verify
whether supplementation of high cholesterol would
result in:
- lowering of APP hypermetabolism
- better survival of neurons in crucial areas like the fore-
brain cholinergic system, hippocampus and some neocor-
tical areas
- better preservation of cognitive functions
Implications of the hypothesis
If the hypothesis is proved to be true it should first of all
change negative attitude towards blood high cholesterol
levels in clinical practice. In particular the use of statins in
older subjects with neurological disorders should be
revised. Recently there is an increasing number of reports
indicating uncertainties related to this issue [20,27]. How-
ever this should be handled with care, since some authors
even acknowledging the positive role of cholesterol in the
brain do not exclude some beneficial actions of this group
of drugs see e.g. [7]. Nevertheless, if the hypothesis is val-
idated it may result in changes in some diet recommenda-
tions, especially while considering that definitely not in
all cases high blood cholesterol must result in arterioscle-
rosis, this is supported by findings indicating homo-
cysteine and not cholesterol as the primary vessel
damaging factor in this disease [28], see also a strong crit-
icism of the concept "blaming" cholesterol as a primary
factor in the disease [29].
Moreover it would open up new alleys in brain function
studies in general and AD in particular. It would imply the
need of widening our understanding of the activity of cho-
lesterol in the plasmalemma of neurons and mechanisms
by which cholinergic receptors interact with plasmalem-
mal cholesterol.
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